BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36252018)

  • 1. 14-3-3τ drives estrogen receptor loss via ERα36 induction and GATA3 inhibition in breast cancer.
    Garan LAW; Xiao Y; Lin WC
    Proc Natl Acad Sci U S A; 2022 Oct; 119(43):e2209211119. PubMed ID: 36252018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and localization of estrogen receptor in human breast cancer and its clinical significance.
    Li L; Wang Q; Lv X; Sha L; Qin H; Wang L; Li L
    Cell Biochem Biophys; 2015 Jan; 71(1):63-8. PubMed ID: 25113640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERα36-GPER1 Collaboration Inhibits TLR4/NFκB-Induced Pro-Inflammatory Activity in Breast Cancer Cells.
    Notas G; Panagiotopoulos A; Vamvoukaki R; Kalyvianaki K; Kiagiadaki F; Deli A; Kampa M; Castanas E
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sphingosine kinase 1 activation by estrogen receptor α36 contributes to tamoxifen resistance in breast cancer.
    Maczis MA; Maceyka M; Waters MR; Newton J; Singh M; Rigsby MF; Turner TH; Alzubi MA; Harrell JC; Milstien S; Spiegel S
    J Lipid Res; 2018 Dec; 59(12):2297-2307. PubMed ID: 30315000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOX4-mediated FBW7 transcriptional upregulation confers Tamoxifen resistance in ER+ breast cancers via GATA3 downregulation.
    Sharma A; Thacker G; Mishra M; Singh AK; Upadhyay V; Sanyal S; Trivedi AK
    Life Sci; 2022 Aug; 303():120682. PubMed ID: 35662647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXC1 is involved in ERα silencing by counteracting GATA3 binding and is implicated in endocrine resistance.
    Yu-Rice Y; Jin Y; Han B; Qu Y; Johnson J; Watanabe T; Cheng L; Deng N; Tanaka H; Gao B; Liu Z; Sun Z; Bose S; Giuliano AE; Cui X
    Oncogene; 2016 Oct; 35(41):5400-5411. PubMed ID: 27041579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression patterns of ERα66 and its novel variant isoform ERα36 in lactotroph pituitary adenomas and associations with clinicopathological characteristics.
    Mahboobifard F; Bidari-Zerehpoosh F; Davoudi Z; Panahi M; Dargahi L; Pourgholami MH; Sharifi G; Izadi N; Jorjani M
    Pituitary; 2020 Jun; 23(3):232-245. PubMed ID: 32026205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From ERα66 to ERα36: a generic method for validating a prognosis marker of breast tumor progression.
    Chamard-Jovenin C; Jung AC; Chesnel A; Abecassis J; Flament S; Ledrappier S; Macabre C; Boukhobza T; Dumond H
    BMC Syst Biol; 2015 Jun; 9():28. PubMed ID: 26080803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Relative Expression of ERα Isoforms ERα66 and ERα36 Controls the Cellular Response to 24R,25-Dihydroxyvitamin D3 in Breast Cancer.
    Verma A; Cohen DJ; Jacobs TW; Boyan BD; Schwartz Z
    Mol Cancer Res; 2021 Jan; 19(1):99-111. PubMed ID: 33082240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance.
    Song T; Zhang H; Zhao Q; Hu Z; Wang Z; Song Y; Zhang Z
    Breast Cancer Res; 2024 Feb; 26(1):33. PubMed ID: 38409088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-specific mutation of GATA3 disrupts the transcriptional regulatory network governed by Estrogen Receptor alpha, FOXA1 and GATA3.
    Takaku M; Grimm SA; De Kumar B; Bennett BD; Wade PA
    Nucleic Acids Res; 2020 May; 48(9):4756-4768. PubMed ID: 32232341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and Biological Significance of
    Nagel A; Szade J; Iliszko M; Elzanowska J; Welnicka-Jaskiewicz M; Skokowski J; Stasilojc G; Bigda J; Sadej R; Zaczek A; Markiewicz A
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30995757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A transcriptional complex composed of ER(α), GATA3, FOXA1 and ELL3 regulates IL-20 expression in breast cancer cells.
    Lee JY; Park YJ; Oh N; Kwack KB; Park KS
    Oncotarget; 2017 Jun; 8(26):42752-42760. PubMed ID: 28514748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 14-3-3Tau regulates ubiquitin-independent proteasomal degradation of p21, a novel mechanism of p21 downregulation in breast cancer.
    Wang B; Liu K; Lin HY; Bellam N; Ling S; Lin WC
    Mol Cell Biol; 2010 Mar; 30(6):1508-27. PubMed ID: 20086099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The RNA-binding protein HuR regulates GATA3 mRNA stability in human breast cancer cell lines.
    Licata LA; Hostetter CL; Crismale J; Sheth A; Keen JC
    Breast Cancer Res Treat; 2010 Jul; 122(1):55-63. PubMed ID: 19728080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TET2 is a component of the estrogen receptor complex and controls 5mC to 5hmC conversion at estrogen receptor cis-regulatory regions.
    Broome R; Chernukhin I; Jamieson S; Kishore K; Papachristou EK; Mao SQ; Tejedo CG; Mahtey A; Theodorou V; Groen AJ; D'Santos C; Balasubramanian S; Farcas AM; Siersbæk R; Carroll JS
    Cell Rep; 2021 Feb; 34(8):108776. PubMed ID: 33626359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 14-3-3τ promotes breast cancer invasion and metastasis by inhibiting RhoGDIα.
    Xiao Y; Lin VY; Ke S; Lin GE; Lin FT; Lin WC
    Mol Cell Biol; 2014 Jul; 34(14):2635-49. PubMed ID: 24820414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen enhances stemness and promotes metastasis of ERα36
    Wang Q; Jiang J; Ying G; Xie XQ; Zhang X; Xu W; Zhang X; Song E; Bu H; Ping YF; Yao XH; Wang B; Xu S; Yan ZX; Tai Y; Hu B; Qi X; Wang YX; He ZC; Wang Y; Wang JM; Cui YH; Chen F; Meng K; Wang Z; Bian XW
    Cell Res; 2018 Mar; 28(3):336-358. PubMed ID: 29393296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indole-3-carbinol triggers aryl hydrocarbon receptor-dependent estrogen receptor (ER)alpha protein degradation in breast cancer cells disrupting an ERalpha-GATA3 transcriptional cross-regulatory loop.
    Marconett CN; Sundar SN; Poindexter KM; Stueve TR; Bjeldanes LF; Firestone GL
    Mol Biol Cell; 2010 Apr; 21(7):1166-77. PubMed ID: 20130088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of ERα36 in Development and Tumor Malignancy.
    Thiebaut C; Konan HP; Guerquin MJ; Chesnel A; Livera G; Le Romancer M; Dumond H
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32526980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.